Clinical Trials Logo

Clinical Trial Summary

In patients with symptoms of mixed incontinence (loss of urine associated with coughing/sneezing/laughing, and loss of urine associated with the strong urge to void), is surgical treatment with tension free vaginal tape or pharmacological treatment with tolterodine more effective? What are the parameters predictive of success or failure with either forms of treatment? What are the parameters predictive of the necessity for further treatment after primary treatment?

Patients will be randomised to having surgical or pharmacological treatment for their mixed incontinence symptoms. They will be assessed subjectively and objectively pre-treatment and after treatment at intervals up to 3 months.


Clinical Trial Description

The aim of the study is to compare the efficacy and effect on the patient subsequent to pharmacological treatment with single dose tolterodine compared to surgical treatment with TVT in patients with urodynamically demonstrated mixed urinary incontinence, but with prevailing symptoms of stress incontinence. Secondary aims are the identification of parameters predictive of success or failure for the two treatments (echography, duration of the symptoms) and the necessity for further treatment after the primary therapy. The primary objective is to reduce the number of incontinence episodes after treatment with either modality.

The design will be randomisation of 40 patients, with 20 in the surgical group and 20 in the pharmacological treatment group. The patients must be female and aged between 35 and 70. They should not be intending to fall pregnant and be capable of completing a questionnaire about their incontinence symptoms and quality of life, a diary of their incontinence episodes and account of the passing of their urine, as well as be able to give informed consent to participate in the study.

The study will last for approximately 12 months and will consist of 5 visits. At the first visit, the patient will be seen to verify their suitability for admission into the study, have baseline blood tests, and urine analysis, as well as urodynamic assessment. They will also be given a diary to fill out an account of their urine passing which they will be asked to complete for the course of 3 days prior to their next appointment.

At the second appointment, the patient's diary will be collected and reviewed, a quality of life questionnaire will be completed, as well as an ultrasound scan performed to assess the thickness of the wall of their bladder. The patients will then be randomised into the pharmacological and surgical groups. Those in the surgical group will be put onto the waiting list for TVT (which they will have within 2 weeks of the second appointment), or commence treatment with tolterodine.

4 weeks after either treatment the patients are seen again and their symptoms are assessed and a second diary of the urinary behaviour (completed by the patient for the week prior to this visit) will be reviewed.

On the final visit, which will be after 12 weeks of treatment, the patients undergo urodynamic testing, diary assessment, symptom assessment, a quality of life questionnaire is completed and an appraisal of the patient's satisfaction with their treatment is collected. The discussion of need for any further treatment will take place and at this stage the patient may then have their treatment changed to either the tolterodine or surgery depending on their symptoms. These patients will then be finally seen after six months to review their progress. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00523068
Study type Interventional
Source Imperial College London
Contact Demetri C Panayi, BSc MRCOG
Phone 02078861016
Email d.panayi@imperial.ac.uk
Status Not yet recruiting
Phase Phase 4
Start date September 2007
Completion date January 2010

See also
  Status Clinical Trial Phase
Completed NCT02001714 - Group Learning Achieves Decreased Incidents of Lower Urinary Symptoms N/A
Completed NCT00904969 - A Pre-Market Study of the American Medical Systems (AMS) Transobturator Male Sling System for the Treatment of Male Stress Urinary Incontinence N/A
Completed NCT00190814 - Effectiveness and Safety of Duloxetine in Women Experiencing Urinary Leakage Due to Physical Stress and Urge. Phase 3
Completed NCT00190827 - Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine) Phase 3
Terminated NCT00247286 - Weighted Vaginal Cones Versus Biofeedback in the Treatment of Urodynamic Stress Incontinence: a Randomized Trial. Phase 4
Completed NCT01959347 - Combined Treatment for Mixed Incontinence Phase 3
Completed NCT00244296 - To Determine How Effective Duloxetine is in Treating Women 65 Years and Older With Symptoms of Stress Urinary Incontinence, or With a Combination of Stress Urinary Incontinence and Urge Urinary Incontinence Symptoms Phase 4
Not yet recruiting NCT05570071 - A Study of the Use of Vaginal Radiofrequency Therapy in Treatment of SUI. N/A
Completed NCT02334878 - Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence Phase 3
Completed NCT01382602 - Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical Study Phase 3
Completed NCT03296462 - Hip External Rotation Physical Therapy Trial N/A
Recruiting NCT02750878 - Surgical Consent Process for Trans-obturator Tape Slings. N/A
Completed NCT02296099 - Trial Liposomal Bupivacaine Following Retropubic Suburethral Sling for Stress Urinary Incontinence Phase 4
Completed NCT02599051 - Transobturator Verus Single Incision Slings N/A
Completed NCT00138749 - An 8 Week Study Looking At The Efficacy, Toleration And Safety Of SS-RBX For Stress Urinary Incontinence. Phase 2
Terminated NCT03614611 - Canadian Experience With Contiform Intravaginal Device For The Treatment Of Stress Incontinence N/A
Completed NCT03722719 - The Knack on Female Stress Urinary Incontinence N/A
Active, not recruiting NCT02275728 - Pelvic Floor Muscle Training With and Without Biofeedback in Women With Stress Urinary Incontinence N/A
Terminated NCT01358214 - Quality of Life After Tension Free Transvaginal Sling / Tape Operation With a Titanized Surgical Tape (TiLOOP® Tape) N/A
Active, not recruiting NCT01323426 - Treatment of Stress Urinary Incontinence by Injection of Autologous Muscle Fibers Into the Urethral Sphincter. Phase 1/Phase 2